WANBURY
Back to Income Statement
|
WANBURY Last 5 Year Revenue History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Net Sales | ₹600 Cr | ₹578 Cr | ₹500 Cr | ₹511 Cr | ₹393 Cr |
What is the latest Revenue of WANBURY ?
| Year | Revenue |
|---|---|
| Mar2025 | ₹600 Cr |
| Mar2024 | ₹578 Cr |
| Mar2023 | ₹500 Cr |
| Mar2022 | ₹511 Cr |
| Mar2021 | ₹393 Cr |
How is Revenue of WANBURY Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2025 | ₹600 Cr | 3.77 | |
| Mar2024 | ₹578 Cr | 15.63 | |
| Mar2023 | ₹500 Cr | -2.26 | |
| Mar2022 | ₹511 Cr | 30.23 | |
| Mar2021 | ₹393 Cr | - | |
Compare Revenue of peers of WANBURY
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| WANBURY | ₹872.7 Cr | -6.1% | -3% | 45.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹431,628.0 Cr | 3.5% | 5.6% | 11.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹167,975.0 Cr | -1.3% | 4.5% | 16.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹145,804.0 Cr | -0.7% | 6.9% | 47.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹108,829.0 Cr | 1.3% | 5.1% | 17.5% | Stock Analytics | |
| CIPLA | ₹106,768.0 Cr | -1.9% | -0.3% | -6% | Stock Analytics | |
WANBURY Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| WANBURY | -6.1% |
-3% |
45.5% |
| SENSEX | -4.1% |
-5.8% |
5.8% |
You may also like the below Video Courses